)
)
)
Pacylex Pharmaceuticals Inc.
Pacylex Pharmaceuticals is a clinical stage oncology company pioneering a new class of anti-cancer compounds, NMT inhibitors. Pacylex is developing oral zelenirstat, the first in class NMTi, for heme cancers (Phase 1/2 study in acute myeloid leukemia patients (NCT06613217), Orphan and Fast Track Designations) with PR and CRs in DLBCL and AML, and for solid tumors as:
- ADC payload - recent data showed the potency of an ADC with zelenirstat was over 20-1,000x the potency of zelenirstat itself against prostate and breast cancer cell lines including a breast cancer line resistant to other ADCs.
- Synergy with immune checkpoint inhibitors (ICIs) like Keytruda, to overcome tumor resistance to ICIs. Recent animal data showed synergy between zelenirstat and anti-PD-1 in an ICI resistant head and neck cancer model, and the mechanism is understood. A Phase 2 clinical study is ready to go.
- Zelenirstat is the most potent radiosensitizer. A Phase 2 clinical study in glioblastoma patients is ready to go.
Address
EdmontonCanada
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)